Baidu
map

PLoS One特刊:负面,阴性结果与无结果文章合集

2015-03-07 MedSci评论 MedSci原创

PLoS One杂志推出了一个特刊,名称为The Missing Pieces,专门刊发阴性结果,无结果或无法得出结论的研究论文。PLoS One在业界一直存在争议,有褒有贬,但无论如何,经过短短数年成长,已成为期刊界重要的一分子之一。此次刊发特刊,PLoS的编辑们表示负结果对科学研究同样有价值同样重要,可以向科学家提供平衡的观点,可以节约宝贵的科研投入。The Missing Pieces: A

PLoS One杂志推出了一个特刊,名称为The Missing Pieces,专门刊发阴性结果,无结果或无法得出结论的研究论文。


PLoS One在业界一直存在争议,有褒有贬,但无论如何,经过短短数年成长,已成为期刊界重要的一分子之一。此次刊发特刊,PLoS的编辑们表示负结果对科学研究同样有价值同样重要,可以向科学家提供平衡的观点,可以节约宝贵的科研投入。

The Missing Pieces: A Collection of Negative, Null and Inconclusive Results



编辑对此做出了如下评价:

The publication of negative, null and inconclusive results is important to provide scientists with balanced information and avoid the duplication of efforts testing similar hypotheses, which waste valuable time and research resources in the process.

PLOS ONE considers all work that makes a contribution to the field, independent of impact. This includes negative findings which are valuable to the community in cases where the result is illuminating in the context of previous work.

具体链接www.ploscollections.org/missingpieces

实际上,有关阴性结果文章是否有价值,一直存在争议。在此前还有一本专门刊发阴性结果的期刊问世:Journal of Negative Results in BioMedicine,不过据MedSci编辑查询,目前未进入SCI收录。

那么阴性结果,负面结果或无结论结果,是否有价值呢?一般在研究过程中,大家都喜欢阳性结果,尤其是基础研究中,一些阴性结果,往往被冠以“此次实验操作欠佳”而抛弃,最终得出的都是阳性结果。从某种程度上,这种方式已影响到成果的转化。因为大量基础研究成果,到其它实验室并不能很好地重复,甚至不能重复。

不过,临床研究中,一般认为阴性结果可能比较阳性结果更重要。在四大医学期刊中,据有关机构统计,约有30%文章为阴性结果。这一点与基础研究有很大差别。

虽然,阴性结果一般被认为是不光彩的,但从科学意义上说,阴性结果同样重要,如果只汇报阳性结果,很容易造成发表偏倚,制造出各种假象。MedSci小编认为,临床研究中,对阴性结果的重视,使得临床研究可重复性很高;而基础研究阴性结果几乎无法发表,这也可能是造成大量基础研究结果难以重复的重要原因之一。

研究中如何正确呈现结果,显得至关重要。在最早iPS诱导时,实际上,出现iPS的概率相当低,大量尝试都是失败的,只有极少数能成功诱导出iPS,但最终产生了划时代的成果。而在普通的实验中,如果抛弃阴性结果,可能会带来重要信息的丢失,可能并不利于科学进步。PLoS One对阴性结果的发表,也许推动学界对阴性结果,无法得出结论的结果,给予更客观地评价。

当然,MedSci编辑仔细审查这一期合集,并没有读者的担心,虽然都是发表阴性结果或负面结果,但文章质量并不比正刊的质量差。下面列举一些文章:

Lack of an Antibacterial Response Defect in Drosophila Toll-9 Mutant

Karine Narbonne-Reveau, Bernard Charroux, Julien Royet

T Cells Detect Intracellular DNA but Fail to Induce Type I IFN Responses: Implications for Restriction of HIV Replication

Randi K. Berg, Stine H. Rahbek, Emil Kofod-Olsen, Christian K. Holm, Jesper Melchjorsen, David G. Jensen, Anne Louise Hansen, Louise B. Jørgensen, Lars Ostergaard, Martin Tolstrup, Carsten S. Larsen, Søren R. Paludan, Martin R. Jakobsen, Trine H. Mogensen

Impact of a Participatory Intervention with Women’s Groups on Psychological Distress among Mothers in Rural Bangladesh: Secondary Analysis of a Cluster-Randomised Controlled Trial

Kelly Clarke, Kishwar Azad, Abdul Kuddus, Sanjit Shaha, Tasmin Nahar, Bedowra Haq Aumon, Mohammed Munir Hossen, James Beard, Anthony Costello, Tanja A. J. Houweling, Audrey Prost, Edward Fottrell

A Capsaicin (8%) Patch in the Treatment of Severe Persistent Inguinal Postherniorrhaphy Pain: A Randomized, Double-Blind, Placebo-Controlled Trial

Joakim M. Bischoff, Thomas K. Ringsted, Marian Petersen, Claudia Sommer, Nurcan Üçeyler, Mads U. Werner

Gameplay as a Source of Intrinsic Motivation in a Randomized Controlled Trial of Auditory Training for Tinnitus

Derek J. Hoare, Nicolas Van Labeke, Abby McCormack, Magdalena Sereda, Sandra Smith, Hala Al Taher, Victoria L. Kowalkowski, Mike Sharples, Deborah A. Hall

High LRRK2 Levels Fail to Induce or Exacerbate Neuronal Alpha-Synucleinopathy in Mouse Brain

Martin C. Herzig, Michael Bidinosti, Tatjana Schweizer, Thomas Hafner, Christine Stemmelen, Andreas Weiss, Simone Danner, Nella Vidotto, Daniela Stauffer, Carmen Barske, Franziska Mayer, Peter Schmid, Giorgio Rovelli, P. Herman van der Putten, Derya R. Shimshek

Curated MicroRNAs in Urine and Blood Fail to Validate as Predictive Biomarkers for High-Risk Prostate Cancer

Nikhil Sapre, Matthew K. H. Hong, Geoff Macintyre, Heather Lewis, Adam Kowalczyk, Anthony J. Costello, Niall M. Corcoran, Christopher M. Hovens

Lack of Evidence for mtDNA as a Biomarker of Innate Immune Activation in HIV Infection

Adam S. Lauring, Tzong-Hae Lee, Jeffrey N. Martin, Peter W. Hunt, Steven G. Deeks, Michael Busch

Lack of Association between Measles Virus Vaccine and Autism with Enteropathy: A Case-Control Study

Mady Hornig, Thomas Briese, Timothy Buie, Margaret L. Bauman, Gregory Lauwers, Ulrike Siemetzki, Kimberly Hummel, Paul A. Rota, William J. Bellini, John J. O'Leary, Orla Sheils, Errol Alden, Larry Pickering, W. Ian Lipkin

Why Publishing Everything Is More Effective than Selective Publishing of Statistically Significant Results

Marcel A. L. M. van Assen, Robbie C. M. van Aert, Michèle B. Nuijten, Jelte M. Wicherts

Two Failures to Replicate High-Performance-Goal Priming Effects

Christine R. Harris, Noriko Coburn, Doug Rohrer, Harold Pashler

Failure to Replicate Depletion of Self-Control

Xiaomeng Xu, Kathryn E. Demos, Tricia M. Leahey, Chantelle N. Hart, Jennifer Trautvetter, Pamela Coward, Kathryn R. Middleton, Rena R. Wing

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1789647, encodeId=d65e1e896470c, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sat May 09 20:15:00 CST 2015, time=2015-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17995, encodeId=54da1e995d3, content=阴性结果需要大样本才能排除二类错误, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=drhqh240, createdTime=Mon Mar 09 11:01:00 CST 2015, time=2015-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17980, encodeId=eea61e980c1, content=不错的做法, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=MedSci客户端网友, createdTime=Mon Mar 09 08:04:00 CST 2015, time=2015-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17950, encodeId=005a1e950a2, content=还是需要, beContent=null, objectType=article, channel=null, level=null, likeNumber=177, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11a91616246, createdName=CRAZYDAFF, createdTime=Sun Mar 08 14:10:00 CST 2015, time=2015-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17921, encodeId=028f1e921aa, content=MedSci评论合理, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=223.104.5.**, createdTime=Sun Mar 08 10:31:00 CST 2015, time=2015-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17894, encodeId=62831e89475, content=阴性结果也是结果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=222, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3yz0JbjHQ7nicJU7lHMOu0Itf3Zv3VBzEvK3k4AFPBXhiaxIRNGVI33GicoRXQEjkaasjdlWKwZuwcyhDP9Jibqt5ct/0, createdBy=f1281613275, createdName=zhouanxiu, createdTime=Sat Mar 07 21:18:00 CST 2015, time=2015-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17883, encodeId=9fad1e883a2, content=非好不错的, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Sat Mar 07 20:55:00 CST 2015, time=2015-03-07, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1789647, encodeId=d65e1e896470c, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sat May 09 20:15:00 CST 2015, time=2015-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17995, encodeId=54da1e995d3, content=阴性结果需要大样本才能排除二类错误, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=drhqh240, createdTime=Mon Mar 09 11:01:00 CST 2015, time=2015-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17980, encodeId=eea61e980c1, content=不错的做法, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=MedSci客户端网友, createdTime=Mon Mar 09 08:04:00 CST 2015, time=2015-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17950, encodeId=005a1e950a2, content=还是需要, beContent=null, objectType=article, channel=null, level=null, likeNumber=177, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11a91616246, createdName=CRAZYDAFF, createdTime=Sun Mar 08 14:10:00 CST 2015, time=2015-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17921, encodeId=028f1e921aa, content=MedSci评论合理, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=223.104.5.**, createdTime=Sun Mar 08 10:31:00 CST 2015, time=2015-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17894, encodeId=62831e89475, content=阴性结果也是结果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=222, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3yz0JbjHQ7nicJU7lHMOu0Itf3Zv3VBzEvK3k4AFPBXhiaxIRNGVI33GicoRXQEjkaasjdlWKwZuwcyhDP9Jibqt5ct/0, createdBy=f1281613275, createdName=zhouanxiu, createdTime=Sat Mar 07 21:18:00 CST 2015, time=2015-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17883, encodeId=9fad1e883a2, content=非好不错的, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Sat Mar 07 20:55:00 CST 2015, time=2015-03-07, status=1, ipAttribution=)]
    2015-03-09 drhqh240

    阴性结果需要大样本才能排除二类错误

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1789647, encodeId=d65e1e896470c, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sat May 09 20:15:00 CST 2015, time=2015-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17995, encodeId=54da1e995d3, content=阴性结果需要大样本才能排除二类错误, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=drhqh240, createdTime=Mon Mar 09 11:01:00 CST 2015, time=2015-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17980, encodeId=eea61e980c1, content=不错的做法, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=MedSci客户端网友, createdTime=Mon Mar 09 08:04:00 CST 2015, time=2015-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17950, encodeId=005a1e950a2, content=还是需要, beContent=null, objectType=article, channel=null, level=null, likeNumber=177, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11a91616246, createdName=CRAZYDAFF, createdTime=Sun Mar 08 14:10:00 CST 2015, time=2015-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17921, encodeId=028f1e921aa, content=MedSci评论合理, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=223.104.5.**, createdTime=Sun Mar 08 10:31:00 CST 2015, time=2015-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17894, encodeId=62831e89475, content=阴性结果也是结果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=222, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3yz0JbjHQ7nicJU7lHMOu0Itf3Zv3VBzEvK3k4AFPBXhiaxIRNGVI33GicoRXQEjkaasjdlWKwZuwcyhDP9Jibqt5ct/0, createdBy=f1281613275, createdName=zhouanxiu, createdTime=Sat Mar 07 21:18:00 CST 2015, time=2015-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17883, encodeId=9fad1e883a2, content=非好不错的, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Sat Mar 07 20:55:00 CST 2015, time=2015-03-07, status=1, ipAttribution=)]
    2015-03-09 MedSci客户端网友

    不错的做法

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1789647, encodeId=d65e1e896470c, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sat May 09 20:15:00 CST 2015, time=2015-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17995, encodeId=54da1e995d3, content=阴性结果需要大样本才能排除二类错误, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=drhqh240, createdTime=Mon Mar 09 11:01:00 CST 2015, time=2015-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17980, encodeId=eea61e980c1, content=不错的做法, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=MedSci客户端网友, createdTime=Mon Mar 09 08:04:00 CST 2015, time=2015-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17950, encodeId=005a1e950a2, content=还是需要, beContent=null, objectType=article, channel=null, level=null, likeNumber=177, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11a91616246, createdName=CRAZYDAFF, createdTime=Sun Mar 08 14:10:00 CST 2015, time=2015-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17921, encodeId=028f1e921aa, content=MedSci评论合理, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=223.104.5.**, createdTime=Sun Mar 08 10:31:00 CST 2015, time=2015-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17894, encodeId=62831e89475, content=阴性结果也是结果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=222, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3yz0JbjHQ7nicJU7lHMOu0Itf3Zv3VBzEvK3k4AFPBXhiaxIRNGVI33GicoRXQEjkaasjdlWKwZuwcyhDP9Jibqt5ct/0, createdBy=f1281613275, createdName=zhouanxiu, createdTime=Sat Mar 07 21:18:00 CST 2015, time=2015-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17883, encodeId=9fad1e883a2, content=非好不错的, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Sat Mar 07 20:55:00 CST 2015, time=2015-03-07, status=1, ipAttribution=)]
    2015-03-08 CRAZYDAFF

    还是需要

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1789647, encodeId=d65e1e896470c, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sat May 09 20:15:00 CST 2015, time=2015-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17995, encodeId=54da1e995d3, content=阴性结果需要大样本才能排除二类错误, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=drhqh240, createdTime=Mon Mar 09 11:01:00 CST 2015, time=2015-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17980, encodeId=eea61e980c1, content=不错的做法, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=MedSci客户端网友, createdTime=Mon Mar 09 08:04:00 CST 2015, time=2015-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17950, encodeId=005a1e950a2, content=还是需要, beContent=null, objectType=article, channel=null, level=null, likeNumber=177, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11a91616246, createdName=CRAZYDAFF, createdTime=Sun Mar 08 14:10:00 CST 2015, time=2015-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17921, encodeId=028f1e921aa, content=MedSci评论合理, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=223.104.5.**, createdTime=Sun Mar 08 10:31:00 CST 2015, time=2015-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17894, encodeId=62831e89475, content=阴性结果也是结果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=222, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3yz0JbjHQ7nicJU7lHMOu0Itf3Zv3VBzEvK3k4AFPBXhiaxIRNGVI33GicoRXQEjkaasjdlWKwZuwcyhDP9Jibqt5ct/0, createdBy=f1281613275, createdName=zhouanxiu, createdTime=Sat Mar 07 21:18:00 CST 2015, time=2015-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17883, encodeId=9fad1e883a2, content=非好不错的, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Sat Mar 07 20:55:00 CST 2015, time=2015-03-07, status=1, ipAttribution=)]
    2015-03-08 223.104.5.**

    MedSci评论合理

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1789647, encodeId=d65e1e896470c, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sat May 09 20:15:00 CST 2015, time=2015-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17995, encodeId=54da1e995d3, content=阴性结果需要大样本才能排除二类错误, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=drhqh240, createdTime=Mon Mar 09 11:01:00 CST 2015, time=2015-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17980, encodeId=eea61e980c1, content=不错的做法, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=MedSci客户端网友, createdTime=Mon Mar 09 08:04:00 CST 2015, time=2015-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17950, encodeId=005a1e950a2, content=还是需要, beContent=null, objectType=article, channel=null, level=null, likeNumber=177, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11a91616246, createdName=CRAZYDAFF, createdTime=Sun Mar 08 14:10:00 CST 2015, time=2015-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17921, encodeId=028f1e921aa, content=MedSci评论合理, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=223.104.5.**, createdTime=Sun Mar 08 10:31:00 CST 2015, time=2015-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17894, encodeId=62831e89475, content=阴性结果也是结果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=222, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3yz0JbjHQ7nicJU7lHMOu0Itf3Zv3VBzEvK3k4AFPBXhiaxIRNGVI33GicoRXQEjkaasjdlWKwZuwcyhDP9Jibqt5ct/0, createdBy=f1281613275, createdName=zhouanxiu, createdTime=Sat Mar 07 21:18:00 CST 2015, time=2015-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17883, encodeId=9fad1e883a2, content=非好不错的, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Sat Mar 07 20:55:00 CST 2015, time=2015-03-07, status=1, ipAttribution=)]
    2015-03-07 zhouanxiu

    阴性结果也是结果的

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1789647, encodeId=d65e1e896470c, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sat May 09 20:15:00 CST 2015, time=2015-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17995, encodeId=54da1e995d3, content=阴性结果需要大样本才能排除二类错误, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=drhqh240, createdTime=Mon Mar 09 11:01:00 CST 2015, time=2015-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17980, encodeId=eea61e980c1, content=不错的做法, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=MedSci客户端网友, createdTime=Mon Mar 09 08:04:00 CST 2015, time=2015-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17950, encodeId=005a1e950a2, content=还是需要, beContent=null, objectType=article, channel=null, level=null, likeNumber=177, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11a91616246, createdName=CRAZYDAFF, createdTime=Sun Mar 08 14:10:00 CST 2015, time=2015-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17921, encodeId=028f1e921aa, content=MedSci评论合理, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=223.104.5.**, createdTime=Sun Mar 08 10:31:00 CST 2015, time=2015-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17894, encodeId=62831e89475, content=阴性结果也是结果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=222, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3yz0JbjHQ7nicJU7lHMOu0Itf3Zv3VBzEvK3k4AFPBXhiaxIRNGVI33GicoRXQEjkaasjdlWKwZuwcyhDP9Jibqt5ct/0, createdBy=f1281613275, createdName=zhouanxiu, createdTime=Sat Mar 07 21:18:00 CST 2015, time=2015-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17883, encodeId=9fad1e883a2, content=非好不错的, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Sat Mar 07 20:55:00 CST 2015, time=2015-03-07, status=1, ipAttribution=)]
    2015-03-07 xiaoai5777

    非好不错的

    0

相关资讯

PLoS Med:“死亡测试”能告诉你,时间到了

最新研究显示一项简单的血液测试可以预测一个人是否有可能死亡——尽管他们没有生病。研究人员惊讶的发现“死亡测试”可预测一个健康的人在五年内死于医疗状况的可能性,相关文章发表在PLOS医学上。他们发现有四种生物标记物在身体中一般显示比较“微弱”。通过血液测试,生物标记物状态不好的人在五年内死亡的可能性增加5倍。“人们很好奇这些生物标记是如何反映死于各种不同类型疾病如心脏病、癌症的可能性的,它们在身体内

喻海良:发Plos One,基金就给评“差”?

刚刚看了科学网头条,《NSFC评审丑态》。其文中说“这其中又包含几类,其一、出身不好:要么发了一些付费的SCI,要么是将文章发在PLoS One或Advanced Material Research等名声不佳的期刊上,对不起,你犯忌了,只能无情地归为C类(不予资助)”。 看了之后,不吐不快。个人认为,如果一个基金评审人看了有人发“Plos One”就把申请书给枪毙了,这是一种严重的不负责任的行为

谁动了Plos One的饭碗?

有分析人员发现,Plos One目前的发行量呈现快速下降的趋势,这种趋势的具体原因现在仍不好确定,但其中来自其他开放期刊的挑战肯定是一种因素,那么到底是那些期刊对Plos One可能产生威胁,也好让大家提前有个应对。这里尝试分析如下。 一、开放类文章相对比例不断增加 现在web of science数据库新增加开放类文献分析模块,根据这个模块可以对开放类文献所占比例进行分析,从分析

PLoS 要求论文作者公开数据

世界最大的开放获取期刊PLoS宣布要求论文作者公开数据。官方博客表示,PLoS使命及开放获取运动的核心是不受限制的即刻访问研究结果。然而,如果没有结果背后的数据,论文的可用性不大。 PLoS一向要求论文作者向希望复制研究结果的同行提供数据,现在它修改了数据分享政策,要求作者在论文出版的同时立即公开所有数据,不能有任何限制。从3月3日开始,所有向PLoS递交论文的作者必须要

2014年PLOS One发表1200多篇论文更错说明

前几天,查看某期刊,发现有不少的“论文更错说明”。也是,我好奇心下来了,想看看这些年那些期刊的论文更错说明最多。一查不知道,在过去10年中发表“论文更错说明”的居然全是大期刊,排在前六位的,我估摸着科学网上绝大部分科研人员都知道。 第一位:Physical Review B,十年间发表论文更错说明1261篇。 第二位:Plos One,一年间发表论文更错说明1240篇。 第三位:Proce

PLoS ONE:研究发现长相与智商相关

最近的一项研究表明,我们也许可以通过观察长相判断一个人的智商高低。而在这一过程中,人们从男性长相中“读取”到的智商,与真实情况更为接近。这项研究由捷克布拉格查尔斯大学的心理与历史科学系的科研人员主持,文章结果上月发表在 PLOS ONE 杂志上。 研究人员一共招募了两批志愿者来进行这一实验。第一组参与者包括80名(男女各40名)来自布拉格大学理学院生物系的学生,研究人员

Baidu
map
Baidu
map
Baidu
map